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Backgrounds/Aims: Routine bile duct resection as part of the typical oncological resection for patients with advanced 
gallbladder cancer remains controversial with regard to, ultimately, curative value. The aim of this study was to compare 
oncological outcomes for patients undergoing surgery for gallbladder cancer with or without bile duct resection. 
Methods: We recruited, for the purpose of this study, all patients who underwent surgical resection for T2 and T3 
gallbladder cancer at Severance hospital, Seoul, Korea, during the period January 2000 and December of 2011. The 
patient data was reviewed retrospectively. Results: The patients (n=149) recruited to participate in the study were div-
ided into two groups according to their bile duct resection status: The bile duct resection group (BDR group, n=54); 
and, the bile duct non-resection group (BDNR group, n=95). Significant difference was found in lymph node retrieval 
between BDR and BDNR groups (15 vs. 5, respectively with p＜0.001). There was no significant difference between 
the two groups with regard to the five year survival rate (43% in BDR group vs. 57% in BDNR group, p=0.339). 
Following multivariate analysis, lymph node metastasis, advanced T-stage, and total retrieved lymph nodes ＜6 were 
independent prognostic factors for poor survival in patients with T2 and T3 gallbladder cancer. Conclusions: The find-
ings revealed by the current study suggest that the role of bile duct resection might be limited to improved staging, 
and offers no advantage in long-term survival. However, in view of the foregoing and given the minimal increase in 
morbidity associated with BDR, it should be actively considered as a treatment option for patients who present with 
findings suspicious for invasion around hepatoduodenal ligament. (Ann Hepatobiliary Pancreat Surg 2018;22:42-51)
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INTRODUCTION
Gallbladder adenocarcinoma, historically, has been con-
sidered an incurable malignancy with a dismal prognosis.1,2 
Complete surgical resection seems to represent the only 
potentially effective curative treatment for resectable gall-
bladder cancer. Regional lymph node dissection is indis-
pensable and invaluable for the accurate staging of gall-
bladder cancer.3,4 The extent of resection in gallbladder 
cancer is usually determined by the pre- and intraoperative 
assessment of the nature and extent of the tumor invasion. 
According to the National Comprehensive Cancer Network 
(NCCN) guidelines,5 simple cholecystectomy is considered 
appropriate to treat T1a gallbladder cancer. In patients 
with more advanced localized disease, en bloc hepatic re-
section and lymphadenectomy are recommended.5 Whether 
routine bile duct resection is medically indicated and 
“should be performed”, in many cases, remains a judgment 
call on the part of the surgeon because the surgical in-
dication may remain unclear, even to direct inspection. 
There is a lack of objective evidence to support an in-
creased long-term survival rate after routine resection, 
while increased morbidity has been reported.6-8 Several re-
cent studies have focused on identifying prognostic factors 
conductive to long-term survival in those patients afflicted 
with advanced gallbladder cancer. Although several varia-
Jin Hong Lim, et al. Role of common bile duct resection in T2 and T3 gallbladder cancer patients  43
bles such as lymphovascular invasion, the operative meth-
od and total lymph node count of ＜6 have been proposed 
no definitive consensus has ever been achieved.3,9,10
Current guidelines5 suggest that a selective approach to 
bile duct resection be implemented and utilized, with the 
aim of ensuring a negative margin. Despite the relative 
paucity of rarified, substantial medical evidence, others 
recommend routine bile duct resection in an effort to in-
crease chances of disease-free survival.9 The aim of this 
study was to more precisely assess and identify the role 
of bile duct resection for T2 and T3 gallbladder cancer, 
vis-à-vis the specific issues of oncological and long-term 
survival benefit.
MATERIALS AND METHODS
Patients
For the purpose of this study, all patients who under-
went surgical resection for documented diagnoses of gall-
bladder cancer at the Severance hospital, Seoul, Korea 
during the period January 2000 through December of 
2011 were identified. Patients were included for further 
analysis if the pathological and surgical report confirmed 
T2 or T3 gallbladder cancer, and an R0 margin. The pa-
tients recruited for the study were divided into two 
groups: The bile duct resected (BDR group); and, the bile 
duct non-resected group (BDNR group). Formal compar-
ison was made between the clinicopathologic character-
istics and the follow-up data referable to the patients in 
each of the two groups.
Preoperative studies
All patients underwent preoperative abdominal ultra-
sonography and computed tomography. Endoscopic ultra-
sonography was used to identify and assess the degree of 
penetration of the focal malignancy into the gallbladder 
wall in patients with suspected invasive lesions. Positron 
emission tomography was performed to evaluate distant 
metastases after laparoscopic or open cholecystectomy in 
patients with incidentally-diagnosed gallbladder cancer. 
Blood levels of carbohydrate antigen 19-9 (CA 19-9) were 
evaluated as a tumor marker. The medical history of each 
participant patient was scrutinized, and all patients under-
went physical examinations, baseline laboratory testing, 
electrocardiography and chest imaging.
Surgical strategy
The standard surgical procedure undertaken was radical 
cholecystectomy (involving cholecystectomy and segment 
4b/5 liver resection around the gallbladder bed), with a 
margin of approximately 2 cm. However, some surgeons 
did not perform liver resections (in those cases where in-
traoperative inspection and the findings did not reveal 
gross liver invasion). Lymph node (LN) dissection was 
classified as either “D1” or “D2” dissection. The D1 was 
defined as “dissection around the hepatoduodenal liga-
ment (including LN removal around the cystic duct, bile 
duct, portal vein, and hepatic artery) and dissection of 
LNs around the gastrohepatic ligament”. The D2 dis-
section was defined as “D1 dissection plus dissection of 
the celiac LNs, pancreaticoduodenal LNs, and para-aortic 
LNs”. Although the extent of lymph node dissection often 
depended on a judgement call by the individual surgeon, 
D1 dissection was routinely performed by all surgeons. 
Dissection of para-aortic lymph nodes and other nodes be-
longing to the N2 group were usually conducted when 
lymph node enlargement was observed intraoperatively. 
Para-aortic lymph nodes were excluded from the total 
lymph node count. The nature and extent of additional or 
combined resection was determined by tumor extent. 
Decision regarding bile duct resection depended on the 
surgeons’ visual and tactile assessment in the operating 
room. During the study period within the institution, no 
consensus was achieved among the surgeons regarding the 
issue of “routine” bile duct resection. Due to the lack of 
consensus, some surgeons performed routine bile duct re-
section, while others opted to perform the procedures 
which they considered medically reasonable and necessary 
based upon dynamic assessment of the intraoperative find-
ings during the actual surgery. Regardless, we also noted 
that complete clearance of the hepatoduodenal ligament 
including bile duct resection, was always performed in the 
patients with positive cystic duct resection margins, as 
well as those patients suspected to have direct invasion 
around the hepatoduodenal ligament as identified in pre-
operative imaging studies.
Perioperative and follow-up data
During surgery, operative procedures, operative time, 
intraoperative blood loss and transfusion requirement were 
carefully documented. Complications were registered ac-
44  Ann Hepatobiliary Pancreat Surg Vol. 22, No. 1, February 2018
Fig. 1. Distribution of T-stage according to residual tumor.
cording to the Clavien-Dindo Classification of Surgical 
Complications.11 Patients with advanced T-stage (T≥3) or 
lymph node metastasis (N≥1) were recommended for ad-
juvant chemotherapy, radiotherapy, or chemoradiation 
therapy. Patients were referred to medical oncologists, and 
each oncologist chose a different treatment regimen ac-
cording to experience and preference. The adjuvant ther-
apy was not provided if the patient declined the treatment, 
or if the patient’s performance status was greater than two 
based on the Eastern Cooperative Oncology Group 
guidelines. CA 19-9 levels were checked as a tumor mark-
er, and an abdominal-pelvic computed tomography scan 
was performed at three months postoperative. If and when 
tumors recurred, chemotherapy and/or radiation therapy 
were initiated dependent upon patient status. Local re-
currence of tumors, such as the trocar site recurrence, was 
controlled by surgical excision. The tumor recurrences 
were categorized as “local recurrences” or “distant meta-
stases”. The documented date of the last follow-up was 
set at January 2015.
Statistical analysis
For each quantitative variable, the Shapiro-Wilk test 
was used as a test of normality. Continual data were com-
pared using Student’s t-test or Mann-Whitney U test, as 
appropriate. Categorical variables were compared using 
the Chi-square test or Fisher’s exact test, as appropriate. 
Survival curves were calculated by the Kaplan-Meier 
method; differences in the survival curves were compared 
by the log-rank test. Multivariate analysis identified prog-
nostic factors of survival using the Cox proportional haz-
ard model. Statistical analyses were performed with 
Statistical Package for the Social Sciences v.20 software 
(IBM-SPSS Inc., Chicago, IL USA). Statistical sig-
nificance was defined by p-values ＜0.05.
RESULTS
Of the 271 patients who underwent surgery for gall-
bladder cancer within the study period, 211 (78%) patients 
underwent R0 resection. Of these 211 patients, 149 (55%) 
had T2 or T3 disease confirmed pathologically and were 
included for further analysis (Fig. 1).
Clinicopathologic characteristics of patients divided in-
to BDR group and BDNR group are summarized in Table 
1. Eighty-nine patients (60%) received liver resection; of 
these subjects, 73 (49%) received partial or complete re-
section of segment 4b/5. Trisectionectomy was performed 
in eight patients (5%), central bisectionectomy in three pa-
tients (2%) and hemihepatectomy in five patients (3%). 
Combined resection of adjacent organs was performed in 
six patients (4%) of BDR group and included the pancreas 
(n=3), duodenum (n=1), and colon (n=2) (Fig. 2). Of the 
50 patients with T3 tumors, invasion into the liver (n=30), 
serosa (n=17) and bile duct (n=3) were diagnoseded and 
documented.
The median follow-up period for BDR group was 50 
months (range: 0-145 months) and for BDNR group was 
80 months (range: 0-152 months). During the follow-up 
period, recurrence occurred in 64 patients (43%). Local 
recurrences (n=8) occurred at the liver resection margin 
(n=4), hilar area (n=3) and trocar site (n=1).
Given the clinicopathologic heterogeneity (Table 1) 
among the two groups, a subgroup analysis was per-
formed for those who underwent liver resection (n=89) 
with or without BDR (Table 2). In this subset of patients, 
only eleven of 47 patients underwent BDR for suspected 
invasion.
While median operative time and postoperative hospital 
stay was significantly increased in the BDR group, com-
plication rates were seemingly unaffected. Complications 
(according to Clavien-Dindo Classification) were com-
parable between BDR and BDNR group (p=0.558). 
Among 10 (21%) complications in BDR group, three were 
grade 1 and included ascites and seroma. One patient had 
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Table 1. Clinicopathologic characteristics
Variables BDR group (N=54) BDNR group (N=95) p-value
Median age, years (range)   61 (38-82)  62 (48-80) 0.358
Gender, n Male 23 (43%) 44 (46%) 0.661
Initial presentation    0.122
  Incidental with reoperation  18 (33%) 44 (46%)  
  Non-incidental  36 (67%) 51 (54%)  
Liver resections, n  47 (87%) 42 (44%) ＜0.001
Pathology, n     
  T-stage T2 29 (54%) 70 (74%) 0.013
 T3 25 (46%) 25 (26%)  
  N stage N0 30 (56%) 66 (70%) 0.049
 N1 11 (20%) 20 (21%)  
 N2 13 (24%)  9 (10%)  
  AJCC 7th stage, n II 16 (30%) 51 (54%) 0.011
 IIIA 14 (26%) 15 (16%)  
 IIIB 11 (20%) 20 (21%)  
 IVB 13 (24%)  9 (10%)  
  Lymphovascular invasion Yes  8 (15%) 16 (17%) 0.746
 No 46 (85%) 79 (83%)  
  Perineural invasion Yes 12 (22%)  9 (10%) 0.032
 No 42 (78%) 86 (91%)  
  Differentiation Well  8 (15%) 39 (41%) 0.003
 Moderate 25 (46%) 38 (40%)  
 Poor 10 (19%) 11 (12%)  
 Unknown 11 (20%) 7 (7%)  
  Median lymph nodes retrieved (Interquartile range)    
    All lymph nodes (except LN 16)  14.5 (8-18.25)  5 (0-13) ＜0.001
    LN 7,8,9  3 (0-6) 0 (0-3) ＜0.001
    LN 12c  1 (1-2) 1 (1-1) 0.662
    LN 12ec  3.5 (1-5) 1 (0-4) 0.005
    LN 13  1 (0-2) 0 (0-1) 0.001
    LN 16  3 (0-6) 0 (0-5) 0.031
Adjuvant therapy, n  27 (50%) 47 (50%) 0.951
Recurrence, n  26 (48%) 38 (40%) 0.334
BDR group, bile duct resection group; BDNR group, bile duct non-resection group; LN 16, para-aortic lymph nodes; LN 7,8,9, 
lymph nodes around the gastrohepatic ligament; LN12c, pericholecystic lymph nodes; LN 12ec, lymph nodes around the hep-
atoduodenal ligament, excluding pericholecystic nodes; LN 13, retropancreatic lymph nodes
Fig. 2. Type of operative pro-
cedures. BDNR group, bile duct
non-resection group; BDR group,
bile duct resection group; Chole,
cholecystectomy; LN, lymph node
dissection; CBD, common bile 
duct resection; Radical chole+etc.,
Radical cholecystectomy and com-
bined resection; PPPD, Pylorus- 
preserving pancreaticoduodenec-
tomy.
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Table 2. Comparison between bile duct resection and bile duct non-resection groups for combined liver resected patients
Variables  BDR group (N=47) BDNR group (N=42) p-value
Median age, years (range) 60 (38-82) 63 (48-75) 0.258
Gender, n Male 19 22 0.259
Female 28 20
Median operative time, min (range)   372 (216-739)   221 (112-556) ＜0.001
Median intraoperative blood loss, ml (range)  350 (0-2300)  275 (0-2100) 0.432
Complications, n 10 (21%)  5 (12%) 0.558
Median postoperative hospital stay, days (range) 14.5 (7-43) 12 (7-83) 0.025
Differentiation, n Well  7 (19%) 15 (39%) 0.071
Moderate/poor 29 (81%) 24 (62%)
Lymphovascular invasion, n  7 (15%)  5 (12%) 0.680
Perineural invasion, n 11 (23%)  4 (10%) 0.081
Lymph node metastasis, n 20 (43%) 13 (31%) 0.258
T-stage, n T2 24 (51%) 26 (62%) 0.303
T3 23 (49%) 16 (38%)
AJCC 7th stage, n II 14 (30%) 20 (48%) 0.105
IIIA 13 (28%)  9 (21%)
IIIB  9 (19%) 10 (24%)
IVB 11 (23%) 3 (7%)
Median lymph nodes retrieved (Interquartile range)
  All lymph nodes (except LN 16)      15 (8.00-19.00)       9 (4.75-15.25) 0.006
  LN 7,8,9 4 (0-6) 1.50 (0-5.25) 0.115
  LN 12c 1 (1-2)   1 (1-1.75) 0.742
  LN 12ec 3 (1-5)   2 (0-5.25) 0.379
  LN 13 1 (0-2) 0 (0-1) 0.013
  LN 16 3 (0-6) 0 (0-6) 0.302
BDR group, bile duct resection group; BDNR group, bile duct non-resection group; LN 16, para-aortic lymph nodes; LN 7,8,9, 
lymph nodes around the gastrohepatic ligament; LN12c, pericholecystic lymph nodes; LN 12ec, lymph nodes around the hep-
atoduodenal ligament, excluding pericholecystic nodes; LN 13, retropancreatic lymph nodes
a grade 2 complication with chyle drainage. Four patients 
had grade 3a complications and included pigtail insertions 
for fluid collection. Remaining two patients had grade 3b 
complications due to wound repair under general 
anesthesia.
Para-aortic lymph node (LN 16) dissection was per-
formed more frequently in the BDR group (29 patients 
(62%) vs. 18 patients (43%), p=0.032).
Twenty-two patients (50%) in the BDR group and 22 
patients (52%) in the BDNR group received adjuvant ther-
apy, p=0.600.
In terms of recurrence, there was no significant differ-
ence between the two groups (21 patients (45%) in the 
BDR group vs. sixteen patients (38%) in the BDNR 
group, p=0.529. Most of the recurrences were distant 
metastasis.
At the end of the follow-up period, 83 patients (56%) 
were still alive. There was a follow-up loss of three pa-
tients (2%) after the discharge from the hospital. The 
5-year disease-free survival and overall survival rates 
were 55% and 54%, respectively. The 5-year overall sur-
vival rates of Stages II, IIIA, IIIB and IVB (according to 
cancer stage using the American Joint Committee on 
Cancer (AJCC) 7th Edition Staging) were 69%, 43%, 51%, 
and 16%, respectively. There were significant differences 
of overall survival rate according to the TNM stage, ex-
cept between stage IIIA and IIIB (p=0.460). Comparisons 
of survival rates (according to TNM) stage are shown in 
Fig. 3.
According to the survival analysis for bile duct re-
section, there was no evidence of survival benefit of bile 
duct resection in each of cancer stage (Fig. 4). Further 
survival analysis for liver resected patients has also shown 
no significant role of bile duct resection in both overall 
survival and disease-free survival (Fig. 5).
In univariate analysis for disease-free survival, bile duct 
resection (p=0.048) was one indicator of poor survival 
outcome. However, in multivariate analyses, lymph node 
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Fig. 3. Survival curves according to American Joint Committee on Cancer Staging Manuam 7th edition TNM stage. (A) 
Disease-free survival. (B) Overall survival.
metastasis (p=0.021), T3 stage vs. T2 stage (p=0.001), and 
total retrieved lymph nodes ＜6 vs. ≥6 (p＜0.001) were 
the independent prognostic factors for poor survival out-
come (Table 3). In multivariate analysis for overall sur-
vival, lymph node metastasis, T3 stage, and the total num-
ber of retrieved lymph nodes ＜6 were the independent 
prognostic factors of poor survival outcome (Table 4).
DISCUSSION
The optimal extent of resection in advanced gallbladder 
cancer patients remains a debated issue. Chiefly, the clin-
ical significance of concomitant bile duct resection re-
mains controversial. Kokudo et al.7 reported no appreci-
able survival benefit secondary to bile duct resection in 
patients with LN metastasis. Sakamoto et al.8 also re-
ported that there was no perceptible survival benefit asso-
ciated with bile duct resection in patients with ≥T2 gall-
bladder cancer. Araida et al.6 analyzed 838 gallbladder 
cancer patients and reported that no survival difference re-
sulted from bile duct resection in patients without direct 
infiltration of the hepatoduodenal ligament.
In the current study, there were no significant, docu-
mented differences in the overall survival between the 
BDR group and BDNR group, even though the BDR 
group patients had more advanced tumors than the BDNR 
group patients. Advanced T-stage, presence of LN meta-
stasis and total LN count of ＜6 were the independent 
prognostic indicators of poor survival outcome in the mul-
tivariate analysis. In other study groups, lymphovascular 
invasion, perineural invasion, LN metastasis, total LN 
count of ＜6 and poor differentiation have been reported 
to be significant prognostic factors in patients with gall-
bladder cancer.3,9,10
Adequate LN assessment is important in patients with 
gastrointestinal cancers,12-14 because insufficient lymph 
node dissection during surgery impedes accurate staging. 
Ito et al.3 reported that the minimum LN requirement for 
adequate gallbladder cancer staging was six nodes. In our 
study, the LN count of ＜6 was also the prognostic factor 
for poor survival outcome in gallbladder cancer patients 
(T2 and T3 stage) who received R0 resection. The BDR 
group had more LNs removed than the BDNR group. 
Specifically, the LNs around the retropancreatic area were 
more frequently retrieved in the BDR group. Although 
bile duct resection did not affect the overall survival of 
gallbladder cancer patients, bile duct resection could be 
helpful for more accurately staging the disease.
Anatomically, the lymphatics around the hepatoduodenal 
ligament are the first lymphatic channels draining the 
gallbladder.15 Tumor cell-spread into the hepatoduodenal 
ligament is very frequently observed in advanced gall-
bladder cancer. In 2014, pathologists in Japan reported 
70.6% lymphatic/venous/perineural invasion of gallbladder 
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Fig. 4. Survival curves comparing the BDR and BDNR groups. (A) Overall survival for Stage II. (B) Overall survival for Stage
IIIA. (C) Overall survival for Stage IIIB. (D) Overall survival for Stage IVB. BDNR group, Bile duct non-resection group;
BDR group, Bile duct resection group.
Fig. 5. Survival curves comparing the BDR and BDNR groups for liver resection patients. (A) Overall survival. (B) Disease-free 
survival. BDNR group, Bile duct non-resection group; BDR group, Bile duct resection group.
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Table 3. Univariate and multivariate analyses of prognostic factors for disease-free survival
Variables
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Age, years (n)
  ＜65 (99) vs. ≥65 (50)
Sex (n)
  Male (67) vs. Female (82)
Bile duct resection (n)
  Yes (54) vs. No (95)
Liver resection (n)
  Yes (89) vs. No (60)
Para-aortic LN dissection (n)
  Yes (64) vs. No (81)
Adjuvant therapy (n)
  Yes (74) vs. No (75)
Size, cm (n)
  ＜3 (43) vs. ≥3 (56)
Differentiation (n)
  WD (47) vs. MD to PD (84)
Lymphovascular invasion (n)
  Pos. (24) vs. Neg. (125)
Perineural invasion (n)
  Pos. (21) vs. Neg. (128)
Lymph node metastasis (n)
  Pos. (53) vs. Neg. (96)
T-stage (n)
  T3 (50) vs. T2 (99)
Total retrieved lymph nodes (n) 
  ＜6 (58) vs. ≥6 (91)
 
1.012 (0.607–1.686)
 
1.247 (0.749–2.078)
 
1.668 (0.994–2.799)
 
1.472 (0.863–2.511)
 
0.784 (0.452–1.359)
 
2.035 (1.200–3.451)
 
0.706 (0.356–1.399)
 
0.600 (0.325–1.111)
 
1.926 (1.056–3.513)
 
1.886 (0.977–3.639)
 
1.945 (1.154–3.277)
 
2.870 (1.719–4.793)
 
1.709 (1.020–2.865)
 
0.964
 
0.391
 
0.048
 
0.150
 
0.380
 
0.007
 
0.313
 
0.097
 
0.028
 
0.059
 
0.010
 
＜0.001
 
0.038
 
 
 
 
 
1.743 (0.973–3.121)
 
 
 
 
 
1.538 (0.890–2.658)
 
 
 
 
 
1.938 (0.997–3.767)
 
 
 
1.978 (1.111–3.522)
 
2.497 (1.466–4.251)
 
2.930 (1.605–5.349)
 
 
 
 
 
0.062
 
 
 
 
 
0.123
 
 
 
 
 
0.051
 
 
 
0.021
 
0.001
 
＜0.001
HR, hazard ratio; 95% CI, 95% confidence interval; WD, well differentiated; MD, moderately differentiated; PD, poorly differ-
entiated; Pos., positive; Neg., negative
cancer (T2 and T3).16 In our study, the BDR group had 
more lymph nodes retrieved around the retropancreatic 
area vs. the BDNR group. While other lymph node sta-
tions did not yield more retrieved lymph nodes for the 
BDR group, total number of lymph nodes retrieved was 
significantly higher in the BDR group. These results in-
dicate that lymph node dissection with bile duct resection 
allow more thorough removal of lymph nodes without 
leaving remnant lymph nodes and connective tissue around 
the hepatoduodenal ligament.
Gallbladder cancer can spread in a skipped manner. 
Shimizu et al.17 in pathologic analysis of 50 patients with 
advanced gallbladder cancer, reported that 30 (60%) pa-
tients with the hepatoduodenal ligament invasion includ-
ing five patients with skipped lesion from the primary 
tumor. Among patients with hepatoduodenal ligament in-
vasion, 25 (83%) patients showed cancer cells in extra-
hepatic bile duct and 21 (70%) patients showed occult mi-
croscopic extension. Ogura et al.18 also reported dis-
continuation of tumor invasion into the hepatic 
parenchyma. In terms of these findings, BDR has a poten-
tial benefit of eradicating occult tumor spread at the com-
mon bile duct from gallbladder cancer because of the pos-
sibility of skipped lesions not involving the cystic duct 
margin. We could not, however, affirm any positive effect 
on the long-term survival rate attributable to, or associated 
with, BDR. As such, it may be that the role of BDR may 
be limited to improved staging of gallbladder cancer as 
discussed in our study.
Too, the patients in the BDR group were afflicted with 
more aggressive cancer than the BDNR group and accord-
ingly, surgical resection in the BDR group was also more 
extensive than in the BDNR group. To minimize the bias 
from extensive surgical resection and aggressive cancer in 
BDR group, only the patients with liver resection were 
further analyzed. Bile duct resection involved longer oper-
ative time and long postoperative hospital stays. These 
findings somewhat echo the findings reported by another 
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Table 4. Univariate and multivariate analyses of prognostic factors for overall survival
Variables
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Age, year
  ＜65 vs. ≥65
Sex
  Male vs. Female
Body mass index, kg/m2
  ＜25 vs. ≥25
Bile duct resection
  Yes vs. No
Liver resection
  Yes vs. No
Para-aortic LN dissection
  Yes vs. No
Adjuvant therapy
  Yes vs. No
Size, cm
  ＜3 vs. ≥3
Differentiation
  WD vs. MD to PD
Lymphovascular invasion
  Positive vs. Negative
Perineural invasion
  Positive vs. Negative
Lymph node metastasis
  Positive vs. Negative
T-stage
  T3 vs. T2
Total retrieved LN number 
  ＜6 vs. ≥6
 
0.94 (0.56–1.58)
 
1.17 (0.70–1.97)
 
1.13 (0.67–2.02)
 
1.48 (0.87–2.52)
 
1.50 (0.88–2.57)
 
0.70 (0.40–1.23)
 
1.56 (0.92–2.65)
 
0.63 (0.32–1.27)
 
0.63 (0.34–1.16)
 
1.83 (0.99–3.41)
 
1.99 (1.03–3.86)
 
1.95 (1.15–3.28)
 
3.12 (1.85–5.27)
 
1.87 (1.10–3.19)
 
0.82
 
0.55
 
0.67
 
0.15
 
0.14
 
0.21
 
0.10
 
0.20
 
0.14
 
0.06
 
0.04
 
0.01
 
＜0.01
 
0.02
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.56 (0.78–3.10)
 
2.59 (1.47–4.54)
 
3.14 (1.86–5.32)
 
2.51 (1.44–4.39)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.21
 
＜0.01
 
＜0.01
 
＜0.01
HR, hazard ratio; 95% CI, 95% confidence interval; WD, well differentiated; MD, moderately differentiated; PD, poorly differ-
entiated; LN, lymph node
study group.9 However, we detected no relationship be-
tween bile duct resection and the postoperative complica-
tion rate documented by our study, even though bile duct 
resection always required bilioenteric anastomosis. 
Adverse effects of bile duct resection were almost always 
limited to the immediate postoperative period.
Recurrence of gallbladder cancer is more likely to in-
volve a distant site and frequently occurs in early-stage 
disease.19,20 The peritoneum, liver and retroperitoneal 
lymph nodes tend to be the most common recurrence sites 
of a primary gallbladder cancer.20 This recurrence pattern 
has tended to obscure the potential beneficial effect of bile 
duct resection in obviating a local recurrence. Moreover, 
patients with advanced cancer received adjuvant therapy, 
which has reported favorable results with regard to the 
survival benefits for gallbladder cancer.21,22 The recurrence 
rate in the BDR group was not significantly different from 
that of the BDNR group in this study. To estimate the 
relationship between the recurrence rate and bile duct re-
section, the effectiveness of bile duct resection for accu-
rate lymph node dissection must be evaluated further.
About half of the patients who participated in this study 
received adjuvant therapy. Thirty-three patients in the 
BDR group and 22 patients in BDNR group belonged to 
7th edition AJCC stage of greater than IIIA group. With 
22 patients in each group undergoing adjuvant therapy, 
eleven patients in the BDR group did not receive adjuvant 
therapy due to patient refusal or poor performance status. 
This may have confounded the results in survival analysis. 
Moreover, results of this study may have been influenced 
by heterogeneous nature of the adjuvant therapy. Due to 
limited size of this study, further subgroup analysis on dif-
ferent regimens used was not possible. With more uniform 
adjuvant treatment, better analysis on the efficacy of bile 
duct resection may by possible.
Bile duct resection seems to only influence staging and 
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no benefits on survival have been revealed from this 
study. Accurate staging in gallbladder cancer is still 
important. Lack of survival benefit in bile duct resection 
may be influenced by lack of uniformity in adjuvant 
treatment. Further evaluation of bile duct resection, with 
homogenous adjuvant treatment regimen, should be con-
sidered viable treatment options, for therapeutic and diag-
nostic purposes, and to gain further insights into survival 
benefits.
In conclusion, advanced T-stage, LN metastasis, and 
LN count ＜6 were the independent prognostic factors for 
overall survival and disease-free survival in patients with 
T2 and T3 gallbladder cancer. The BDR group had more 
lymph nodes retrieved vs. the BDNR group, and bile duct 
resection did not increase complication rate. The role of 
bile duct resection may be limited to improved staging 
and without affording any actual long-term survival bene-
fit, based upon the current study. However, without any 
documented, significant increase in morbidity of the BDR 
group, bile duct resection should be actively considered 
as in patients with suspicious invasion around hep-
atoduodenal ligament.
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